The recent approval in South Korea includes both complicated skin and skin structure infections (cSSSI) and right-sided infective endocarditis (SAB/RIE). Cubicin was previously approved in Taiwan (in November
The new entity will have Nordic sales rights for both Orexo’s and ProStrakan’s portfolio including Tostrex, Rectogesic and Droperidol, followed by Rapinyl, Orexo’s patented product for the treatment
Vaccinated travelers were 75% less likely to suffer moderate or severe diarrhea from any cause and 84% less likely to be afflicted by severe diarrhea, according to the
This facility, which has the ability to manufacture lyophilized powders, suspension products, and aqueous and oil solutions, currently manufactures products for both Watson and other third parties, according
The two phase III trials will evaluate the safety and efficacy of retigabine, a first-in-class neuronal potassium channel opener, in patients with refractory partial-onset seizures who are receiving
The law firm Hagens Berman Sobol Shapiro filed the lawsuit on behalf of Springfield, Missouri, resident Patrick Bills who claims that she developed severe hyperglycemia and new onset
Although the FDA does not have to follow the advice of its regulatory committees, in most cases the agency does. Tysabri is approved for multiple sclerosis, although the
According to Lev, it is the first company to submit a licensing application for the acute treatment of hereditary angioedema (HAE) in the US. The FDA has sixty
Recruitment of the first cohort is expected to be completed within approximately eight months, following which data on the primary endpoints, response rate and safety, will be reported.
The drug, LX211, is a next-generation calcineurin inhibitor intended for the treatment of non-infectious posterior, intermediate and panuveitis (an autoimmune disease characterized by chronic inflammation of the eye).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.